SEC Info - PDL Biopharma, Inc. - ‘8-K’ for 6/13/16

SEC Info℠

Home

Help

Please Sign In

PDL Biopharma, Inc. – ‘8-K’ for 6/13/16

On: Monday, 6/13/16, at 4:06pm ET · For: 6/13/16 · Accession #: 882104-16-162 · File #: 0-19756

  As Of                Filer                Filing    For·On·As Docs:Size

 6/13/16  PDL Biopharma, Inc.               8-K:8,9     6/13/16    2:114K

Current Report — Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     16K 
 2: EX-99.1     Press Release                                       HTML      8K

8-K — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 13, 2016

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756

(Commission File Number)



Delaware		94-3023969
(State or Other Jurisdiction of Incorporation)		(I.R.S. Employer Identification No.)

932 Southwood Boulevard

Incline Village, Nevada 89451

(Address of principal executive offices, with zip code)

(775) 832-8500

(Company’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On June 13, 2016, PDL BioPharma, Inc. issued a press release announcing that it has paid the June 13, 2016, quarterly dividend payment. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



Exhibit No.		Description

99.1		Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



PDL BIOPHARMA, INC.
(Company)

By:		/s/ *Peter S. Garcia*
		Peter S. Garcia
		Vice President and Chief Financial Officer

Dated: June 13, 2016

Exhibit Index



Exhibit No.		Description
99.1		Press Release

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period End:	6/13/16	None on these Dates
		List all Filings

↑Top

Filing Submission 0000882104-16-000162 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)